Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

The local gene-sequencing company and a U.S. clothing company face sales restrictions in China as part of that country’s ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Leading American genomic sequencing firm Illumina says it is evaluating Beijing’s announcement with hope of ‘positive ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Illumina's (ILMN) stock slid 5% post-market after it released its Q4 earnings report and reiterated its 2025 guidance, ...

Illumina's revenue has stagnated or declined for several years now, and its total sales for 2024 were $4.3 billion, down from ...

The guidance did not account for the potential impact of the China Ministry of Commerce's decision to add the company to its 'unreliable entity list.' On the other hand, Illumina exceeded analysts ...

On Monday, for the second time in as many business days, Illumina ( ILMN -4.11%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% ...